Some of the Largest Cannabis Companies Will Soon Report Q4 Financials

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This data-driven, fact-based tracker will continually update based on new financial filings so that readers can stay up to date. Companies must file with the SEC or SEDAR and be current to be considered for inclusion.

When we launched this resource in May 2019, companies with quarterly revenue in excess of US$2.5 million qualified. As the industry has scaled and as more companies have gone public, we have raised the minimum several times subsequently, including a move to US$5 million in October 2019, to US$7.5 million in June 2020, to US$10 million in November 2020 and US$12.5 million in August 2021.

Due to the rapid growth in the cannabis industry, we raised the minimum to US$25 million (C$32 million) to qualify for what we are now calling the senior list and introduced a junior list with a minimum of US$12.5 million (C$16.0 million) in September. At the time of our last update in late December, 36 companies qualified for inclusion on the senior list, including 30 filing in U.S. dollars and 6 in the Canadian currency. The junior list now includes 13 reporting in U.S. dollars and 4 in Canadian dollars. On a combined basis, the Public Cannabis Company Revenue & Income Tracker includes 53 companies. There were no additions or deletions this month. We expect to add additional companies in the months ahead, and, due to pending or recently completed mergers, we anticipate some removals as well. We note that Intercure (TASE: INCR) (NASDAQ: INCR), which reports in the Israeli currency, qualifies for the junior list, but we haven’t yet added it due to its different reporting currency.

In May 2019, we added an additional metric, “Adjusted Operating Income”, as we detailed in our newsletter. The calculation takes the reported operating income and adjusts it for any changes in the fair value of biological assets required under IFRS accounting. We believe that this adjustment improves comparability for the companies across IFRS and GAAP accounting. We note that often operating income can include one-time items like stock compensation, inventory write-downs or public listing expenses, and we recommend that readers understand how these non-cash items can impact quarterly financials. Many companies are moving from IFRS to U.S. GAAP accounting, which will reduce our need to make adjustments. Please note that our rankings include only actual reported revenue and not pro forma revenue. We also note that companies with non-cannabis operations must provide segment-level financial reports that detail not only revenue but also operating profit to be have their operating profit included in the tracker. Currently, Jazz Pharma (NASDAQ: JAZZ) and Tilray (TSX: TLRY) (NASDAQ: TLRY) aren’t providing this information.

Since our last update, only Tilray (TSX: TLRY) (NASDAQ: TLRY) has reported among companies reporting in the U.S. currency. It had been expected generate overall revenue of $173 million, with adjusted EBITDA of $14.3 million, but the actual results for its fiscal Q2 ending in November were revenue of $155 million and adjusted EBITDA of $13.8 million. We had shared a negative outlook for Tilray’s cannabis business just ahead of the report, and the actual results were worse than we had expected. Overall cannabis revenue declined 17% sequentially to $58.8 million despite growth in its international business. Its Canadian adult-use sales plunged 30% from Q1 to $34.9 million.

American Dollar Reporting – Public Cannabis Company Revenue Tracker

In February, Scott’s Miracle-Gro (NYSE: SMG) will report its fiscal Q1. The company has already pre-announced that its Hawthorne Gardening sales fell approximately 40% from a year ago. According to Sentieo, overall revenue for the company is expected to have decreased 25% to $561 million, with adjusted EBITDA of -$1 million and EPS of -$0.72. MedMen (CSE: MMEN) (OTC: MMNFF) is expected to report its Q2 in February as well, while Jazz Pharma (NASDAQ: JAZZ) and Innovative Industrial Properties (NYSE: IIPR) will report their Q4 results. Cronos Group (TSX: CRON) (NASDAQ: CRON), which remains delinquent in its filings from Q3, is expected to report in February as well, with revenue expected to have increased 20% sequentially to $18.7 million.

The largest MSOs will begin to report Q4 results in early March, with calls scheduled for Green Thumb Industries (CSE: GTII)(OTC: GTBIF) on 3/1 and Curaleaf (CSE: CURA) (OTC: CURLF) on 3/3. GTI is expected to have generated revenue of $239 million, up 35% from a year ago, with adjusted EBITDA of $83 million. up 35%. Curaleaf revenue is expected to increase 42% to $326 million, with adjusted EBITDA increasing 46% to $78 million.

For companies reporting in the Canadian currency, High Tide (TSXV: HITI) (NASDAQ: HITI) and Organigram (TSX: OGI) (NASDAQ: OGI) both reported results in line with or better than what had been expected during January. High Tide moved up the Canadian rankings to the third spot, with sales increasing sequentially to C$53.9 million during its fiscal Q4 ending in October. The company guided for Q1 revenue of approximately C$70 million, which would rank it second. Organigram fiscal Q1 revenue of C$30.4 million expanded 22% sequentially and 57% from a year ago.

In February, Canopy Growth (TSX: WEED) (NASDAQ: CGC) and Aurora Cannabis (TSX: ACB) (NASDAQ: ACB) from the senior list will report along with Valens (TSX: VLNS) (NASDAQ: VLNS) and Humble & Fume (CSE: HMBL) (OTC: HUMBF) from the junior list. According to Sentieo, Canopy Growth is expected to have experienced a 9% revenue decline in its fiscal Q3 to C$139 million, with adjusted EBITDA of -C$110 million. One unknown is how the company will report the revenue from its German division, that it is divesting. It contributed C$11.9 million to revenue in Q2. Aurora Cannabis is expected to have generated C$58 million in its fiscal Q2, down 14% from a year ago, with adjusted EBITDA of -C$12 million. Valens is expected to have generated C$24.6 million revenue in its fiscal Q4 ending in October, up 53%.

For those interested in more information about companies reporting in January, we publish comprehensive earnings previews for subscribers at 420 Investor, including for Focus List members mentioned here, Canopy Growth, Cronos Group, Curaleaf, Green Thumb Industries, Scotts Miracle-Gro and Valens.

Visit the Public Cannabis Company Revenue Tracker to track and explore the complete list of qualifying companies. We have recently created a way for our readers to access our library of Revenue Tracker articles. For our readers who are interested in staying on top of scheduled earnings calls in the sector, we have have created and continually update the Cannabis Investor Earnings Conference Call Calendar.

Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter